Relmada Therapeutics reported a net loss of $0.22 per share for Q1 2026, slightly missing the forecasted loss of $0.21. Despite this, the stock rose 1.77% in after-hours trading to $7.49. However, by May 19, 2026, premarket trading saw an 8.12% decline to $6.34.
The company's focus on its NDV-01 program and robust cash position were key highlights. Cash balance reached $234 million, providing runway through 2029.
CEO Sergio Traversa stated: ``Our strengthened cash position provides resources to advance clinical programs. The NDV-01 program positions us well to address unmet needs in bladder cancer treatment.''
